Eli Lilly and CompanyLLYNYSE
Loading
Book Value/Share Growth Under PressureDecelerating
Percentile Rank62
3Y CAGR+185.9%
5Y CAGR-7.7%
Year-over-Year Change
Year-over-year book value per share growth
3Y CAGR
+185.9%/yr
vs -69.2%/yr prior
5Y CAGR
-7.7%/yr
Recent acceleration
Acceleration
+255.1pp
Accelerating
Percentile
P62
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 11.12% |
| Q3 2025 | 30.13% |
| Q2 2025 | 15.80% |
| Q1 2025 | 10.98% |
| Q4 2024 | 0.04% |
| Q3 2024 | 5.01% |
| Q2 2024 | 5.71% |
| Q1 2024 | 18.53% |
| Q4 2023 | 1.41% |
| Q3 2023 | 1.42% |
| Q2 2023 | -1.29% |
| Q1 2023 | 4.92% |
| Q4 2022 | 0.48% |
| Q3 2022 | 17.35% |
| Q2 2022 | -3.37% |
| Q1 2022 | 3.69% |
| Q4 2021 | 15.45% |
| Q3 2021 | 13.22% |
| Q2 2021 | -0.74% |
| Q1 2021 | 21.50% |
| Q4 2020 | 16.59% |
| Q3 2020 | 16.94% |
| Q2 2020 | 33.68% |
| Q1 2020 | 18.53% |
| Q4 2019 | -21.84% |
| Q3 2019 | 21.92% |
| Q2 2019 | 12.97% |
| Q1 2019 | -75.33% |
| Q4 2018 | -23.46% |
| Q3 2018 | 22.94% |
| Q2 2018 | -18.96% |
| Q1 2018 | 25.51% |
| Q4 2017 | -18.37% |
| Q3 2017 | 5.57% |
| Q2 2017 | 0.69% |
| Q1 2017 | -0.06% |
| Q4 2016 | -9.58% |
| Q3 2016 | 6.54% |
| Q2 2016 | -2.48% |
| Q1 2016 | 3.14% |